Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 88

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 88
---
 fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

3Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures. 

42

Table of Contents

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:

Nine Months Ended September 30, 2025(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$2,685 $463 $2,222 $(4)$2,226 $1.49 Non-GAAP adjustments:Amortization expense669 93 576 7 570 0.38 Goodwill and other intangible asset impairment charges46 8 37 — 37 0.02 Acquisition/divestiture-related net charges (credits)156 (1)157 — 157 0.10 Restructuring and restructuring-related net charges (credits)247 32 215 — 215 0.14 Investment portfolio net losses (gains) and impairments(0)0 (0)— (0)(0.00)EU MDR implementation costs34 5 29 — 29 0.02 Deferred tax expenses (benefits)— (139)139 — 139 0.09 Discrete tax items— (1)1 — 1 0.00 Adjusted$3,836 $461 $3,375 $3 $3,372 $2.26 

Nine Months Ended September 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income